Home > Newsletters > International Pharmaceutical Regulatory Monitor > PDUFA V Could Jeopardize U.S. Lead Over EU in Cancer Drug Approvals, Expert Says
International Pharmaceutical Regulatory Monitor
August 2012 | Vol. 40 No. 8
PDUFA V Could Jeopardize U.S. Lead Over EU in Cancer Drug Approvals, Expert Says
A new study shows the U.S. outpaces Europe in approving new cancer drugs, but that lead could be in jeopardy under the fifth authorization of the Prescription Drug User Fee Act (PDUFA V), an expert tells IPRM.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.